Verastem (NASDAQ:VSTM) Shares Down 7.8% – Here’s What Happened

Verastem, Inc. (NASDAQ:VSTM – Get Free Report)’s stock price was down 7.8% on Wednesday. The company traded as low as $6.78 and last traded at $6.83. 1,021,681 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 2,585,704 shares. The stock had previously closed at $7.41.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on VSTM. Guggenheim set a $12.00 price target on Verastem and gave the stock a “buy” rating in a research note on Friday, August 7th. Mizuho upped their price objective on shares of Verastem from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, October 16th. Citigroup reiterated a “buy” rating on shares of Verastem in a report on Thursday, October 8th. Alliance Global Partners reissued a “buy” rating on shares of Verastem in a research report on Thursday, October 15th. Finally, Weiss Ratings downgraded shares of Verastem from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 15th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.83.

Read Our Latest Stock Analysis on VSTM

Verastem Price Performance

The stock has a fifty day moving average price of $8.43 and a 200-day moving average price of $6.32. The company has a market cap of $797.77 million, a PE ratio of -3.09 and a beta of 0.45. The company has a debt-to-equity ratio of 11.19, a current ratio of 1.93 and a quick ratio of 1.91.

Verastem (NASDAQ:VSTM – Get Free Report) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.27). The business had revenue of $24.01 million during the quarter, compared to analyst estimates of $26.57 million. Verastem had a negative return on equity of 359.49% and a negative net margin of 178.38%. On average, equities analysts expect that Verastem, Inc. will post -1.88 earnings per share for the current year.

Insider Buying and Selling

In other Verastem news, CEO Dan Paterson sold 44,121 shares of Verastem stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $8.00, for a total transaction of $352,968.00. Following the transaction, the chief executive officer owned 652,712 shares of the company’s stock, valued at $5,221,696. The trade was a 6.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 48,041 shares of company stock worth $386,390. Company insiders own 1.94% of the company’s stock.

Institutional Trading of Verastem

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new stake in Verastem in the 2nd quarter worth approximately $706,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Verastem by 157.2% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 569,195 shares of the biopharmaceutical company’s stock valued at $2,174,000 after acquiring an additional 347,872 shares in the last quarter. Opaleye Management Inc. purchased a new position in shares of Verastem during the 2nd quarter valued at $6,876,000. Exome Asset Management LLC grew its holdings in shares of Verastem by 58.5% during the 1st quarter. Exome Asset Management LLC now owns 636,700 shares of the biopharmaceutical company’s stock valued at $3,375,000 after acquiring an additional 234,957 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its stake in shares of Verastem by 715.1% in the first quarter. Seven Fleet Capital Management LP now owns 123,400 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 108,260 shares during the last quarter. 88.37% of the stock is owned by hedge funds and other institutional investors.

Verastem Company Profile

(Get Free Report)

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.

See Also

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.